Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension

Trial Profile

A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Praliciguat (Primary)
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 23 Jun 2018 Results presented in the Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top